Tibet Cheezheng Tibetan Medicine Co., Ltd.

XSEC:002287 Stock Report

Market Cap: CN¥11.6b

Tibet Cheezheng Tibetan Medicine Past Earnings Performance

Past criteria checks 3/6

Tibet Cheezheng Tibetan Medicine has been growing earnings at an average annual rate of 5.9%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 10.5% per year. Tibet Cheezheng Tibetan Medicine's return on equity is 15.2%, and it has net margins of 26.2%.

Key information

5.9%

Earnings growth rate

5.8%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate10.5%
Return on equity15.2%
Net Margin26.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Tibet Cheezheng Tibetan Medicine makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

XSEC:002287 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,2715941,27960
30 Jun 242,2255951,26759
31 Mar 242,1145861,18661
31 Dec 232,0455811,16259
30 Sep 231,8754941,07548
30 Jun 231,9785521,07052
31 Mar 231,9334781,09351
01 Jan 232,0454731,10755
30 Sep 221,9934291,08373
30 Jun 221,881-401,04573
31 Mar 221,8497001,02772
01 Jan 221,77071698571
30 Sep 211,65772789467
30 Jun 211,6591,17188068
31 Mar 211,66245891167
31 Dec 201,48540482960
30 Sep 201,45441383064
30 Jun 201,40538383857
31 Mar 201,30132876956
31 Dec 191,40336482456
30 Sep 191,32834876845
30 Jun 191,28133174046
31 Mar 191,24032671939
01 Jan 191,21331969737
30 Sep 181,21833968432
30 Jun 181,13732162134
31 Mar 181,08630959330
31 Dec 171,05330158026
30 Sep 171,01829758015
30 Jun 179872985670
31 Mar 179712945520
31 Dec 169682905480
30 Sep 169862795380
30 Jun 169842745320
31 Mar 161,0092745410
31 Dec 159952655290
30 Sep 159842524930
30 Jun 151,0092594720
31 Mar 159792434590
31 Dec 149502384520
30 Sep 149232344050
30 Jun 149062293870
31 Mar 149072183730
31 Dec 139692133780

Quality Earnings: 002287 has a large one-off gain of CN¥228.8M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 002287's current net profit margins (26.2%) are lower than last year (26.3%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 002287's earnings have grown by 5.9% per year over the past 5 years.

Accelerating Growth: 002287's earnings growth over the past year (20.4%) exceeds its 5-year average (5.9% per year).

Earnings vs Industry: 002287 earnings growth over the past year (20.4%) exceeded the Pharmaceuticals industry -2.5%.

Return on Equity

High ROE: 002287's Return on Equity (15.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 03:09
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Tibet Cheezheng Tibetan Medicine Co., Ltd. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Shuchang LiuChangjiang Securities Co. LTD.
Fusheng CheungChina Galaxy International Securities (Hong Kong)
Shanshan LiChina Merchants Securities Co. Ltd.